These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2424251)

  • 1. Presence of chemotactic peptides other than C5a anaphylatoxin in scales of psoriasis and sterile pustular dermatoses.
    Takematsu H; Terui T; Ohkohchi K; Tagami H; Suzuki R; Kumagai K
    Acta Derm Venereol; 1986; 66(2):93-7. PubMed ID: 2424251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantification of chemotactic peptides (C5a anaphylatoxin and IL-8) in psoriatic lesional skin.
    Takematsu H; Tagami H
    Arch Dermatol; 1993 Jan; 129(1):74-80. PubMed ID: 8420495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Demonstration of leukotriene B4 in the scale extracts of psoriasis and inflammatory pustular dermatoses. Correlation with leukocyte chemotactic activity and C5a anaphylatoxin.
    Takematsu H; Terui T; Tagami H
    Acta Derm Venereol; 1986; 66(1):6-10. PubMed ID: 2424218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A leukotactic factor in the stratum corneum of pustulosis palmaris et plantaris: a possible mechanism for the formation of intra-epidermal sterile pustules.
    Tagami H; Ofuji S
    Acta Derm Venereol; 1978; 58(5):401-5. PubMed ID: 82349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Demonstration of neutrophil chemotactic anaphylatoxins in human dandruff.
    Kikuchi T; Horii I; Sakamoto T; Nakayama Y; Tagami H
    Arch Dermatol Res; 1989; 281(7):482-6. PubMed ID: 2610519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psoriasis and leukocyte chemotaxis.
    Tagami H; Iwatsuki K; Takematsu H
    J Invest Dermatol; 1987 Mar; 88(3 Suppl):18s-23s. PubMed ID: 3493302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophil chemotactic activity produced by normal and activated human bronchoalveolar lavage cells.
    Sibille Y; Naegel GP; Merrill WW; Young KR; Care SB; Reynolds HY
    J Lab Clin Med; 1987 Nov; 110(5):624-33. PubMed ID: 2822825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of endotoxin-induced C5-derived chemotactic activity in aqueous humor.
    Rosenbaum JT; Wong K; Perez HD; Raymond W; Howes EL
    Invest Ophthalmol Vis Sci; 1984 Oct; 25(10):1184-91. PubMed ID: 6384121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of a neutrophil chemotactic agent by spermatozoa: role of complement and regulation by seminal plasma factors.
    Clark RA; Klebanoff SJ
    J Immunol; 1976 Oct; 117(4):1378-86. PubMed ID: 977954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotactic peptides modulate adherence of human polymorphonuclear leukocytes to monolayers of cultured endothelial cells.
    Charo IF; Yuen C; Perez HD; Goldstein IM
    J Immunol; 1986 May; 136(9):3412-9. PubMed ID: 3514759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of chemotactic factor inactivator in modulating alveolar macrophage-derived neutrophil chemotactic activity.
    Robbins RA; Justice JM; Rasmussen JK; Russ WD; Thomas KR; Rennard SI
    J Lab Clin Med; 1987 Feb; 109(2):164-70. PubMed ID: 3805869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psoriatic skin lesions contain biologically active amounts of an interleukin 1-like compound.
    Camp RD; Fincham NJ; Cunningham FM; Greaves MW; Morris J; Chu A
    J Immunol; 1986 Dec; 137(11):3469-74. PubMed ID: 3491138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Group B streptococci inhibit the chemotactic activity of the fifth component of complement.
    Hill HR; Bohnsack JF; Morris EZ; Augustine NH; Parker CJ; Cleary PP; Wu JT
    J Immunol; 1988 Nov; 141(10):3551-6. PubMed ID: 3053900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of NAP-1 and related peptides in psoriasis and other inflammatory skin diseases.
    Schröder JM
    Cytokines; 1992; 4():54-76. PubMed ID: 1472917
    [No Abstract]   [Full Text] [Related]  

  • 15. Specific inhibitor of complement (C5)-derived chemotactic activity in systemic lupus erythematosus related antigenically to the Bb fragment of human factor B.
    Perez HD; Hooper C; Volanakis J; Ueda A
    J Immunol; 1987 Jul; 139(2):484-9. PubMed ID: 3648093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Demonstration of anaphylatoxins C3a, C4a and C5a in the scales of psoriasis and inflammatory pustular dermatoses.
    Takematsu H; Ohkohchi K; Tagami H
    Br J Dermatol; 1986 Jan; 114(1):1-6. PubMed ID: 3484631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attachment of human C5a des Arg to its cochemotaxin is required for maximum expression of chemotactic activity.
    Perez HD; Chenoweth DE; Goldstein IM
    J Clin Invest; 1986 Dec; 78(6):1589-95. PubMed ID: 3782473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotactic activity generated in human serum from the fifth component of complement by hydrogen peroxide.
    Shingu M; Nobunaga M
    Am J Pathol; 1984 Nov; 117(2):201-6. PubMed ID: 6388344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutrophil chemoattractant and IL-1-like activity in samples from psoriatic skin lesions. Further characterization.
    Fincham NJ; Camp RD; Gearing AJ; Bird CR; Cunningham FM
    J Immunol; 1988 Jun; 140(12):4294-9. PubMed ID: 3286771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C5a as a model for chemotactic factor-stimulated tyrosine phosphorylation in the human neutrophil.
    Richard S; Farrell CA; Shaw AS; Showell HJ; Connelly PA
    J Immunol; 1994 Mar; 152(5):2479-87. PubMed ID: 8133059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.